Neurogene
NGNE
22 hedge funds and large institutions have $27.6M invested in Neurogene in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
16% more funds holding
Funds holding: 19 → 22 (+3)
33% less capital invested
Capital invested by funds: $41.1M → $27.6M (-$13.4M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$639K |
| 2 |
Jane Street
New York
|
+$152K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$123K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$56.7K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$22.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.78M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$779K |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$451K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$82.3K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$38.1K |
NGNE Hedge Fund Activity: Q3 2014 in Review
22 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2014, worth a combined $27.6M — down 33% from $41.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NGNE positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $639K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.78M sold.
- 22 institutional investors held Neurogene (NGNE) as of Q3 2014, up from 19 in Q2 2014.
- Funds reported $27.6M of Neurogene stock for Q3 2014, down 33% quarter-over-quarter.
- 6 funds opened new Neurogene positions in Q3 2014 and 3 closed out, a net change of +3 holders.
- The largest Neurogene buyer in Q3 2014 was Royce & Associates, an estimated $639K added.
- The largest Neurogene seller in Q3 2014 was Sphera Funds Management, an estimated $1.78M sold.
Based on aggregated 13F filings for Q3 2014.